Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Andy - There are 3 key results of which one (POINT 3 BELOW) is regarded as potentially not statistically significant;

1. Patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24hours after treatment (statistically significant, p=0.018).

2.In addition, the incidence of dry retching/vomiting in the M6G arm compared to
the morphine arm in the 24 hour period after treatment was reduced by 32%
(statistically significant, p= 0.044).

3. The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observed in the morphine arm in the period 6 - 24 hours after treatment. This was the second primary endpoint and approached statistical significance (p=0.052).


You will of course note that we are talking about 1% variance here, and that at the end of the day its on the right side (ie 27% better) - even if this result tests again and is netral (ie No improvement/deterioation) then the trial would have succeeded on 2 out of 3 counts, and have no detrimental effect on the 3rd measure.

Surely that is sucess ?

Flackwell, I agree. The Times (21/2/2006) reported the following:

Its a decent late-stage trial result, said Navid Malik, pharmaceuticals analyst at Collins Stewart.

Agreed folks, just establishing why the fall and a downgrade could be the reason however as my mate Driver points out, ASM dived to 12p last year after Roche pulled out of working with them but the quality of the pipeline has seen a rise to 50pish. CEN has the good results, will pusue the US and has other products on test, hence ny comment speculative only in terms of timescale, this will come good and CEN is undervalued IMO.

Investors Chronicle
23rd February 2007 (page 14)

Relief for CeNeS Investors

CeNeS shares rose by 3% to 8.62p after the company announced encouraging data from late-stage trials of morphine replacement M6G. In post-operative patients, the product provided the same quality of pain relief as morphine, but with reduced nausea. However, the shares dipped after Karl Keegan, analyst at Canaccord Adams, downgraded them from buy to hold. He says the nausea reduction was not statistically significant and that CeNeS could have to do another trial.

Tip Update

The shares are below our buy tip (10p, 20th May 2005). But, with the potential for a licensing deal, they remain a speculative buy.

..........................

Personally, I now consider OXB to be the best punt on prospects of a deal.

I bet CeNeS's management and shareholders are livid with Karl Keegan's (Canaccord) comments about a possible further PIII trial (following the European PIII M6G results last week) although he appears to be correct.

right, all this crap is now history! are any partnering deals gonna happen,if not cen will tread water.

The market gets what its been waiting for,and its down 30%,i give up.

Annoyingly (maybe not now), my trailing stop banked the profit for me Thursday and I was looking to buy them back and add at the same time. Too busy Friday however glad I waited as it looks like the market does not like the comments and downgrades and the possibility of delays to market. I still believe that CEN will deliver M6G, lets face it, it is as good as morphine and without the side affects. I have researched over the weekend and the report has been put out on many pharmaceutical and clinical websites. Staying put for now whilst this bottoms out, I've learnt before that you cannot beat the market with your own loyalty but I will be back in once the dust settles.

andysmith,i will hold and add @6p,think thats the best option for me,feel sorry for those that bought recently @9 on the day of the RNS,i agree long term it should be a winner.

It would appear though that whilst Goldman are selling that others are adding to their holdings. Two recent RNS, Gartmore now exceeded 10% and Unniverstites Superannuation exceeded 3%. Maybe this is why the drop, Goldman may still have >10m shares and the buyers want a cheaper price just in case there are delays? Watching closely here but I have time after this fall. CEN will deliver M6G if as good as reported, the side affects of morphine are not good. I think CENES need to come out and respond to the comments of Karl Keegan and advise whether another phase III for Europe is required before licensing deals are likely.

Announcement today: Gartmore declare a 10.3% (49,977,758 shares) holding in CEN.

True Ludlow,but its had NO impact on the SP!!,
Market knows more than i do.

.

Hope you are right!!,but for now its not good.

capetown, the 32% reduction in dry retching/vomiting for European PIII M6G in comparison to morphine was still an encouraging result. Have you sold?

Ludlow,i agree with all that you are saying,I have NOT sold out,just simply stating that the sp is grimm,i will add @6 p to my other holding and wait.

CeNeS Investor Chronicle 23rd February. I read with interest the report page 14 on CeNeS.. However I disagree with Karl Keegan, analyst at Canaccord Adams who has downgraded from buy to hold.. As he says the nausea reduction was not statistically significant and that CeNeS could have to do another trial..

Trials delivered Stong results with CeNeS saying that M6G showed significant reduction in post operative nausea and vomiting compared to morphine.. That on its own is a major benefit to patients.. Its bad enough being in pain.. Reduction of nausea and vomiting is a key factor.. Thank you CeNeS for all the trials that your company has undertaken to prove that M6G is the better drug.. For pain relief with reduced side effects..

With the Gartmore investment CeNeS will soon bounce back...

So why has the share price bombed again this morning

CEN Level 2:

5 market makers blue.

capetown
I agree not worried I will also add if it dips any lower.